A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
- 26 March 2010
- journal article
- Published by Elsevier BV in Cell Chemical Biology
- Vol. 17 (3), 285-295
- https://doi.org/10.1016/j.chembiol.2010.02.007
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinaseBioorganic & Medicinal Chemistry Letters, 2008
- Activation of tyrosine kinases by mutation of the gatekeeper threonineNature Structural & Molecular Biology, 2008
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences of the United States of America, 2008
- Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast CancerPLoS Biology, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences of the United States of America, 2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 2007
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007